Elan and Biogen said the scientific committee of the European Medicines Agency has issued a positive opinion recommending marketing authorisation for its tysabri multiple sclerosis (MS) treatment.
The committee recommended tysabri be used as single disease modifying therapy either in patients with highly active relapsing-remitting MS who have failed to respond to treatment with a beta-interferon, or in patients who have rapidly evolving severe relapsing-remitting MS.
The positive recommendation will be considered for final marketing approval by the European Commission in June.